Ariyoshi K, Cham F, Rowland-Jones S, Gotch F, McMichael AJ, Whittle H; International Conference on AIDS.

Int Conf AIDS. 1994 Aug 7-12; 10: 53 (abstract no. 165A).

M.R.C. Laboratories, Banjul, The Gambia, West Africa.

OBJECTIVES: To investigate homotypic and heterotypic HIV CTL activities in HIV-1, HIV-2 and dually seropositive individuals. METHODS: Fresh PBMCs were collected from 4 HIV-1, 8 HIV-2 and 2 dually seropositive individuals with relatively high CD4+% or count. CTLs were restimulated with autologous PHA-blasts and fed with 10% of lymphocult-T after a week of culture. CTL activities in week-1 and week-2 cultures were evaluated by a standard 51Chromium release assay using autologous B-cell lines infected with recombinant vaccinias expressing HIV-1 or HIV-2 gag, pol or nef proteins at three E:T ratio (60:1, 30:1 and 15:1). When specific lysis (%) against HIV r.V.V. was 10% greater than control r.V.V. (VSC8) at two E:T ratios, the CTL was regarded as significant. RESULTS: Mean CD4+% of HIV-1, HIV-2 and dually seropositive group was 31.5%, 29.4% and 28% respectively. Significant HIV specific CTL was demonstrated in 50% (2/4) of HIV-1, 87.5% (7/8) of HIV-2 and 100% (2/2) of dually +ve individuals at week-2 of culture. Dual (HIV-1/-2) CTL response against gag and pol protein were seen in 2/2 and 1/2 dually +ve individuals. Heterotypic gag CTL was found in one of 7 (14.3%) investigated HIV-2 +ve individuals whose HLA was A28, 30, B41 and 65 while heterotypic gag CTL was found in one of 2 investigated HIV-1 +ve individual whose HLA was A1, 66, B35 and 37. CONCLUSIONS: HIV specific CTL was frequently demonstrated in HIV-2 and dually +ve individuals. Low frequency of heterotypic CTL in HIV-2 +ve individuals suggests that the majority of HIV-2 +ve individuals will not be protected from HIV-1 infection by CTL. Dually reactive CTL were found to be generated in dually seropositive individuals.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Antigens, CD4
• Gene Products, nef
• Gene Products, pol
• Genes, gag
• Genes, pol
• HIV
• HIV Antigens
• HIV Infections
• HIV Seronegativity
• HIV Seropositivity
• HIV-1
• HIV-2
• HLA Antigens
• T-Lymphocytes, Cytotoxic
• genetics
• immunology

Other ID:

• 94370807

UI: 102209637

From Meeting Abstracts